AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth
Dr Lee is a seasoned biopharmaceutical executive with a proven track record of leading cross-functional…
AdvanCell Admin17 November 2025
TheraPb Phase 1b results featured by Urology Times in an interview with Principal investigator Aaron Hansen
Listen to the interview here: Aaron Hansen, MD, shares key findings from the theraPb trial…
AdvanCell featured as Emerging Company by BioCentury
Read the full article here: AdvanCell: Scaling up lead-212 production, keeping down tox
AdvanCell Admin13 November 2025
AdvanCell to participate in Jefferies Global Healthcare Conference in London
Sydney, Australia – 11 November 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative…
AdvanCell Admin11 November 2025
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising…
AdvanCell Admin18 October 2025
AdvanCell appoints experienced biotech and pharma leader, Andrew Kay, as Chair of the Board of Directors
Kay was instrumental in driving the successful development and commercialization of Xofigo®, the first and…
AdvanCell Admin16 October 2025
Alpha-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer
Anna Karmann, Shahneen Sandhu, Louise Emmett, Oliver Sartor, Clemens Kratochwil, Stephen Rose, Ken Herrmann …
AdvanCell Admin7 October 2025
AdvanCell to Highlight the Potential of Pb-212-based Targeted Alpha Therapies for Cancer at EANM’25
Sydney, Australia – September 29, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer,…
AdvanCell Admin29 September 2025
TheraPb Phase 1b abstract accepted for presentation at ESMO 2025
AdvanCell’s abstract “Results from the Phase 1b Dose Escalation of 212Pb-ADVC001 in PSMA-Positive Metastatic Castration-Resistant…
AdvanCell Admin25 July 2025
AdvanCell’s Chief Medical Officer Anna Karmann interviewed for Journal of Nuclear Medicine Podcast
During SNMMI 2025, our Chief Medical Officer Anna Karmann was interviewed by Journal of Nuclear…
AdvanCell Admin1 July 2025
